(621) USP CHAPTER FOR CHROMATOGRAPHY

All chapter are use full for ADJUSTMENT of chromatography, TLC etc 

In such case some questions arias that

Why adjustment in chromatography ?
How adjustment justified ?

Adjust chromatography

If your method is validated and method are submitted in DMF so
[Different lab may different working processer different instrument, column manufacture different  may be fail in sst which may mention in monograph such case ]

a. Meet system suitability criteria
b. Meet relevant performance characteristics (resolution, Rt, Palt count etc(column manufacture different such case)
c.  why sst or monograph condition not achieved in your lab 
i. Change in Instrument /equipment
ii. Change column manufacture 
iii. Change in reagent /chemicals
iv. Different in operation (one lab to another lab)

How adjustment justified

a. By verified SST
b. By verified any other relevant performance characteristic 
3. Important considerations 
a. Change other those indicated in gc<621> revalidation of procedure
b. Once adjusted, procedure can’t be re-adjusted with without re-validation 
c. Cumulative effect must be evaluated  





 

• Just finished a fun session of HPLC calibration!  Time to unwind and rambler a bit about my day.
  Play remember all HPLC calibration link given below free Headline: Stop Memorizing HPLC SOPs. Start Mastering Them. 🎮🧪We’ve all spent hours poring over SOPs, trying to visualize every step of the HPLC calibration process. But what if you could practice the entire workflow in a risk-free, digital environment? I’m excited to share a project I’ve… Read more: Just finished a fun session of HPLC calibration!  Time to unwind and rambler a bit about my day.
• Dissolution investigation
  In pharmaceutical quality control, when a product fails the S1 stage of dissolution (like the 78% result in your example), you don’t just blindly move on to testing more units at the S2 stage. The very first action in an Out of Specification (OOS) or atypical result investigation is to **”Check the product history.”** Here… Read more: Dissolution investigation
• FDA Propose Rule That Would Help Hold Foreign Tobacco Manufacturers Accountable, Protect Public Health
  product dimensions. For e-cigarettes, manufacturers would also need to provide specifications such as e-liquid volume, battery capacity, and wattage.  To streamline and increase efficiency, in most cases manufacturers would be required to submit information electronically through the FDA’s online system, enabling them to register more quickly. They would also be required to review and update… Read more: FDA Propose Rule That Would Help Hold Foreign Tobacco Manufacturers Accountable, Protect Public Health
• RCA (ROOT CAUSE ANALYSIS) IN PHARMACEUTICAL INDUSTRIES
  RCA (ROOT CAUSE ANALYSIS) IN PHARMACEUTICAL INDUSTRIES AS PER REGULATORY REQUIREMENTS 1. PROBLEM IDENTIFICATION What Happens Clearly define the deviation, OOS, OOT, complaint, breakdown, audit observation, or incident. Includes Deviation description Date & time of occurrence Product/Batch details Area/Department involved Immediate impact assessment Initial containment action 2. DATA COLLECTION What Happens Gather all relevant information… Read more: RCA (ROOT CAUSE ANALYSIS) IN PHARMACEUTICAL INDUSTRIES
• summary of global nitrosamine regulations FDA, EMA, ANVISA, SWISSMEDC, HEALTHCANDA.
  * Nitrosamines are trace chemical impurities. * They are classified as probable human carcinogens. * Global agencies require a strict 3-step risk assessment framework. * Manufacturers must evaluate, test, and fix any impurity risks. 1. The Global CPCA SystemAgencies use the **Carcinogenic Potency Categorization Approach (CPCA)** to set safety limits. This system groups impurities into… Read more: summary of global nitrosamine regulations FDA, EMA, ANVISA, SWISSMEDC, HEALTHCANDA.
• Understanding Analytical Method Validation: Interference and Specificity
  This concept is essential in scientific analysis. When you create a method to measure something (like a drug or a chemical), you must prove that the method only measures that specific substance and isn’t being ‘fooled’ by other things in the mixture.
• How to Manage Your Diet and Mental Health in Shift Duty
  Working irregular hours can take a massive toll on the human body. When the natural circadian rhythm is disrupted by rotating schedules, both physical metabolism and psychological well-being are significantly impacted. However, with the right structural changes, health can be effectively maintained. Below is a practical blueprint designed to help professionals thrive while working non-traditional… Read more: How to Manage Your Diet and Mental Health in Shift Duty
• Troubleshooting Retention Time Shift in HPLC: Causes, Solutions, and Best Practices
  If you run high-performance liquid chromatography (HPLC) assay, you know that consistency is everything. In a validated method, your retention time (RT) should remain rock-steady from injection to injection. But every chromatographer eventually faces that frustrating moment when the peaks start drifting. Suddenly, you are dealing with:System suitability failuresIncorrect peak identificationsImpurity mismatchesTime-consuming laboratory investigations and… Read more: Troubleshooting Retention Time Shift in HPLC: Causes, Solutions, and Best Practices
• Maximizing Efficiency in Modern Quality Control Labs
  Operational excellence is demanded by modern quality control laboratories. Every single day, high testing volumes are managed by laboratory analysts. Accuracy must be maintained during complex testing procedures, including HPLC analysis and Karl Fischer titration. When workflows are optimized, regulatory compliance is easily achieved by pharmaceutical professionals.The Importance of Process StandardizationStandardized testing protocols are utilized… Read more: Maximizing Efficiency in Modern Quality Control Labs
• Global Regulatory Pulse
  Weekly Regulatory Highlights (June 1–3, 2026)
  🇺🇸 FDA Updates 🇪🇺 EMA Updates 🇮🇳 CDSCO Updates 📅 Compliance Watchlist ⚠️ Risks & Considerations Reference drug.com
• Key FDA Updates (Late May–Early June 2026)
  The FDA’s latest updates (June 2026) include several new drug approvals, safety warnings on hidden ingredients in supplements, and upcoming regulatory decisions on therapies for COVID-19, urinary tract infections, smoking cessation, and kidney disease. These developments highlight both immediate consumer safety concerns and major advances in oncology and infectious disease treatments.”)  — 🔑 Key FDA… Read more: Key FDA Updates (Late May–Early June 2026)
• Method validation pharma environment
  ​Breakdown of Table 1-1 (Validation Requirements) ​The table in the document shows which validation qualities are needed for different types of tests:
• Key Pharmacopoeia Updates 2026
  These updates are quite significant because they reshape compliance expectations across different regions and therapeutic areas. Let me break down where the impact is most pronounced: 🌍 Key Pharmacopoeia Updates– Indian Pharmacopoeia 2026    – 121 new monographs, especially in anti-tubercular, anti-diabetic, and anti-cancer drugs.    – First-time inclusion of blood component monographs for transfusion… Read more: Key Pharmacopoeia Updates 2026
• QMS – CAPA MODULE
  STEP-BY-STEP PROCEDURE 1. PURPOSE To describe the steps for initiation, investigation, implementation, effectiveness check and closure of Corrective and Preventive Actions (CAPA) in QMS to ensure product quality and compliance with regulatory requirements. 2. SCOPE This procedure applies to all CAPAs arising from all GxP activities within the organization including manufacturing, QC, QA, engineering, warehouse,… Read more: QMS – CAPA MODULE
• Audit Trail Features pharma, life sciences
  🚀 Building Compliant LIMS Software: Key Audit Trail FeaturesDesigning a pharmaceutical LIMS requires a relentless focus on data integrity, 21 CFR Part 11 compliance, and ALCOA+ principles. Here are the core audit trail features I’m prioritizing for our software modules:Immutable Metadata Logging: Automatically capturing the “Who, What, When, and Why” for every data entry, ensuring… Read more: Audit Trail Features pharma, life sciences
• The International Council for Harmonisation (ICH) Q4 series is a milestone in global regulatory collaboration.
  🌍 Harmonizing Pharmaceutical Quality Testing: ICH Q4 Guidelines The International Council for Harmonisation (ICH) Q4 series is a milestone in global regulatory collaboration.  🔹 Core Guideline (Q4B): Establishes the process for evaluating pharmacopoeial texts across the US, EU, and Japan. Once deemed equivalent, these methods are officially interchangeable.  🔹 Annexes (Q4B-1 to Q4B-14): Cover essential… Read more: The International Council for Harmonisation (ICH) Q4 series is a milestone in global regulatory collaboration.
• Navigating TGA Compliance: Your Friendly Guide to Analytical Method Validation in Sydney
  The pharmaceutical and biotechnology sectors in New South Wales are experiencing an incredible boom. From the bustling research hubs in Macquarie Park and Westmead to the clinical trials happening across Randwick, local innovators are developing next-generation therapeutics. However, bringing a brilliant new molecule or drug formulation from the laboratory bench to the Australian market requires… Read more: Navigating TGA Compliance: Your Friendly Guide to Analytical Method Validation in Sydney
• Cómo Crear PNTs a Prueba de Auditorías: La Lista de Verificación Definitiva de QA
  Escribir un Procedimiento Normalizado de Trabajo (PNT / SOP) no es solo plasmar palabras en un papel; es construir un escudo de cumplimiento para tu planta. Un PNT mal redactado es la causa directa de desviaciones, errores humanos y dolores de cabeza durante las auditorías de la #MHRA o la #FDA. 🛡️Ya sea que estés… Read more: Cómo Crear PNTs a Prueba de Auditorías: La Lista de Verificación Definitiva de QA
• Optimización del análisis HPLC para el control de calidad farmacéutico
  En el competitivo entorno de las empresas farmacéuticas modernas, garantizar la calidad precisa del producto no es solo un requisito regulatorio: es la base de la seguridad del paciente. En el corazón de este aseguramiento de la calidad se encuentra el análisis HPLC (Cromatografía Líquida de Alta Eficiencia), una técnica analítica potente utilizada para identificar,… Read more: Optimización del análisis HPLC para el control de calidad farmacéutico
• Out of specification top  five questions and answers pharma
  Can we average an OOS result with passing retest results to get a passing average? A: Absolutely not. Both FDA and MHRA guidelines strictly prohibit averaging an OOS result with passing retests to “hide” the failure or bring the batch into compliance. Averaging hides the inherent variability of the product. If a retest is performed… Read more: Out of specification top  five questions and answers pharma